Such multiple ‘opportunities’ for AURKA activation could underlie the strong association of AURKA overexpression with cancer, particularly where co-overexpressed with an activating partner such as TPX2 (Asteriti et al., 2010), and underscore the importance of ubiquitin-mediated destruction of AURKA in suppressing excess AURKA activity in interphase. Here, TPX2 is linked to cancer.